NLM Digital Collections

Search

Start Over Collections Health Policy and Services Research ✖Remove constraint Collections: Health Policy and Services Research Subjects Government Regulation ✖Remove constraint Subjects: Government Regulation Publication Year 2017 to 2019 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2017">2017</span> to <span class="to" data-blrl-end="2019">2019</span>

42. Drug safety: preliminary findings indicate persistent challenges with FDA foreign inspections : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, December 10, 2019
Subject(s):
Drug Industry -- legislation & jurisprudence
Government Regulation
Pharmaceutical Preparations -- standards
United States
United States. Food and Drug Administration

43. Substance use disorder: prevalence of recovery homes, and selected states’ investigations and oversight : testimony before the Committee on Finance, United States Senate

Publication:
Washington, DC : United States Government Accountability Office, October 24, 2019
Subject(s):
Fraud -- legislation & jurisprudence
Government Regulation
Substance Abuse Treatment Centers -- legislation & jurisprudence
United States

44. Tribal programs: resource constraints and management weaknesses can limit federal program delivery to tribes : testimony before the Subcommittee for Indigenous Peoples of the United States, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, November 19, 2019
Subject(s):
American Natives -- legislation & jurisprudence
Government Regulation
Minority Health -- economics
Population Groups -- legislation & jurisprudence
United States

45. Generic drug development: stakeholders’ views of risk evaluation and mitigation strategies differ : report to the Chairman, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, October 2019
Subject(s):
Drug Industry -- legislation & jurisprudence
Drugs, Generic -- isolation & purification
Government Regulation
Risk Evaluation and Mitigation -- legislation & jurisprudence
United States
United States. Food and Drug Administration

46. Mental health and substance use: state and federal oversight of compliance with parity requirements varies : report to Congressional committees

Publication:
Washington, DC : United States Government Accountability Office, December 2019
Subject(s):
Drug Users -- legislation & jurisprudence
Government Regulation
Healthcare Disparities -- legislation & jurisprudence
Mental Health Services -- legislation & jurisprudence
Substance-Related Disorders
United States
United States. Department of Health and Human Services
United States.

47. Drug control: the Office of National Drug Control Policy should develop key planning elements to meet statutory requirements : report to Congressional addressees

Publication:
Washington, DC : United States Government Accountability Office, December 2019
Subject(s):
Drug Misuse -- legislation & jurisprudence
Drug Overdose -- prevention & control
Government Regulation
Substance-Related Disorders -- prevention & control
United States
United States. Office of National Drug Control Policy

48. Health care workforce: views on expanding Medicare graduate medical education funding to nurse practitioners and physician assistants : report to Congressional committees

Publication:
Washington, DC : United States Government Accountability Office, December 2019
Subject(s):
Education, Medical, Graduate -- economics
Government Regulation
Health Workforce -- economics
Medicare -- organization & administration
Nurse Practitioners -- legislation & jurisprudence
Physician Assistants -- legislation & jurisprudence
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

49. Enforcement and compliance

Author(s):
Berry, Melissa D., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Crime
Fraud -- prevention & control
Government Regulation
Health Care Reform -- legislation & jurisprudence
Conflict of Interest
Drug Industry -- legislation & jurisprudence
Electronic Health Records -- legislation & jurisprudence
Federal Government
Medicaid -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Opioid-Related Disorders
Prescription Drug Diversion
State Government
Telemedicine -- legislation & jurisprudence
Whistleblowing
Humans
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)
State Children's Health Insurance Program (U.S.)